Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
NCT01042925
Completed
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with trastuzumab (Herceptin) and in combination with trastuzumab and paclitaxel. After the MTD is established for each combination (Phase 2), subjects will be enrolled to evaluate the preliminary efficacy and safety of these combinations in metastatic HER2 positive breast cancer. Both trastuzumab and paclitaxel are used in the treatment of metastatic breast cancer (MBC), but patients can devel... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/09/2016
Locations: Investigational Site Number 1537, Los Angeles, California +8 locations
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
NCT02065466
Withdrawn
1.1. Primary Objectives 1. To determine if nab-paclitaxel and temozolomide can be combined with full dose of bevacizumab for the therapy of patients with newly diagnosed brain metastases of metastatic malignant melanoma. * To define the MTD of the combination (Phase I component). * To determine progression free survival (Phase II component). 1.2. Secondary Objectives 1. To separately evaluate the response rate and duration of both the brain and extra-cranial systemic metastases. 2. To def... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2016
Locations: Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona +1 locations
Conditions: Metastatic Melanoma, Brain Metastases
Register for Updates
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
NCT01288261
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bavituximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel together with bavituximab may kill more tumor cells. PURPOSE: This phas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2016
Locations: Arizona Cancer Center, Tucson, Arizona
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
Effects of Paclitaxel on Intimal Hyperplasia
NCT01454778
Completed
This is a single, one time, limited dose infusion of Paclitaxel, that will potentially prevent recurrent stenosis secondary to intimal hyperplasia when compared to the control group at 10 months.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/15/2016
Locations: Sanford Vascular Associates, Sioux Falls, South Dakota
Conditions: Peripheral Vascular Disease
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer
NCT02718742
Withdrawn
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation maintenance therapy works after cisplatin-based chemotherapy and surgery in treating patients with high-risk bladder cancer. Maintenance therapy, such as paclitaxel albumin-stabilized nanoparticle formulation, can help keep cancer from coming back after it has disappeared following initial chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2016
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Recurrent Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Register for Updates
Phase II Study of ZD6474 in Advanced NSCLC
NCT00290537
Terminated
The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2016
Locations: University of Texas M.D.Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
NCT00423852
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. An autologous peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. PU... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/12/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Register for Updates
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
NCT01447706
Completed
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2016
Locations: Arizona Center for Cancer Care, Glendale, Arizona +9 locations
Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
NCT00002558
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administ... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/11/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Register for Updates
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
NCT00502203
Completed
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/05/2016
Locations: Loma Linda Cancer Institute, Loma Linda, California +3 locations
Conditions: Mixed Tumor, Mullerian
Register for Updates
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
NCT00063258
Terminated
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
04/05/2016
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
NCT01421472
Completed
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/30/2016
Locations: Universito of Birmingham atAlabama, Birmingham, Alabama +37 locations
Conditions: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
Register for Updates